These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17020967)

  • 1. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors.
    Su H; Bodenstein C; Dumont RA; Seimbille Y; Dubinett S; Phelps ME; Herschman H; Czernin J; Weber W
    Clin Cancer Res; 2006 Oct; 12(19):5659-67. PubMed ID: 17020967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer.
    Sunaga N; Oriuchi N; Kaira K; Yanagitani N; Tomizawa Y; Hisada T; Ishizuka T; Endo K; Mori M
    Lung Cancer; 2008 Feb; 59(2):203-10. PubMed ID: 17913282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response.
    Zhou LN; Wu N; Liang Y; Gao K; Li XY; Zhang LF
    World J Surg Oncol; 2015 Mar; 13():111. PubMed ID: 25888731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD147-mediated glucose metabolic regulation contributes to the predictive role of
    Li X; Fu Q; Zhu Y; Wang J; Liu J; Yu X; Xu W
    Mol Carcinog; 2019 Feb; 58(2):247-257. PubMed ID: 30320488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
    Ullrich RT; Zander T; Neumaier B; Koker M; Shimamura T; Waerzeggers Y; Borgman CL; Tawadros S; Li H; Sos ML; Backes H; Shapiro GI; Wolf J; Jacobs AH; Thomas RK; Winkeler A
    PLoS One; 2008; 3(12):e3908. PubMed ID: 19079597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.
    Takahashi R; Hirata H; Tachibana I; Shimosegawa E; Inoue A; Nagatomo I; Takeda Y; Kida H; Goya S; Kijima T; Yoshida M; Kumagai T; Kumanogoh A; Okumura M; Hatazawa J; Kawase I
    Clin Cancer Res; 2012 Jan; 18(1):220-8. PubMed ID: 22019513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
    Mileshkin L; Hicks RJ; Hughes BG; Mitchell PL; Charu V; Gitlitz BJ; Macfarlane D; Solomon B; Amler LC; Yu W; Pirzkall A; Fine BM
    Clin Cancer Res; 2011 May; 17(10):3304-15. PubMed ID: 21364032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
    Ihle NT; Paine-Murrieta G; Berggren MI; Baker A; Tate WR; Wipf P; Abraham RT; Kirkpatrick DL; Powis G
    Mol Cancer Ther; 2005 Sep; 4(9):1349-57. PubMed ID: 16170026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging.
    Solomon B; Binns D; Roselt P; Weibe LI; McArthur GA; Cullinane C; Hicks RJ
    Mol Cancer Ther; 2005 Sep; 4(9):1417-22. PubMed ID: 16170034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation.
    Keam B; Lee SJ; Kim TM; Paeng JC; Lee SH; Kim DW; Jeon YK; Chung DH; Kang KW; Chung JK; Heo DS
    J Thorac Oncol; 2015 Aug; 10(8):1189-94. PubMed ID: 26200273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.
    Benz MR; Herrmann K; Walter F; Garon EB; Reckamp KL; Figlin R; Phelps ME; Weber WA; Czernin J; Allen-Auerbach MS
    J Nucl Med; 2011 Nov; 52(11):1684-1689. PubMed ID: 22045706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.
    Koizumi T; Fukushima T; Gomi D; Kobayashi T; Sekiguchi N; Mamiya K; Tateishi K; Katou A; Oguchi K
    Med Oncol; 2017 Sep; 34(10):169. PubMed ID: 28864950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
    van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
    Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging.
    Li D; Zou S; Cheng S; Song S; Wang P; Zhu X
    Mol Pharm; 2019 Aug; 16(8):3469-3476. PubMed ID: 31283253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.
    Dai D; Li XF; Wang J; Liu JJ; Zhu YJ; Zhang Y; Wang Q; Xu WG
    Int J Cancer; 2016 Feb; 138(4):1003-12. PubMed ID: 26334931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction.
    Kanazu M; Maruyama K; Ando M; Asami K; Ishii M; Uehira K; Minomo S; Matsuda Y; Kawaguchi T; Atagi S; Ogawa Y; Kusunoki Y; Takada M; Kubo A
    Clin Lung Cancer; 2014 May; 15(3):182-7. PubMed ID: 24518101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
    Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
    Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of gefitinib sensitivity with radioiodinated PHY based on EGFR expression.
    Yoshimoto M; Hirata M; Kanai Y; Naka S; Nishii R; Kagawa S; Kawai K; Ohmomo Y
    Biol Pharm Bull; 2014; 37(3):355-60. PubMed ID: 24583857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.